[1] WHO. Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. WHO/HTM/TB/2011.6. Geneva:World Health Organization, 2011.
[2] World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402.Geneva:World Health Organization, 2008.
[3] 唐神结.耐药结核病防治手册.北京:人民卫生出版社,2009:44-150.
[4] Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. Infect Drug Resist, 2011, 4:129-135.
[5] Jacobson KR,Theron D,Victor TC,et al.Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis, 2011,53(4):369-472.
[6] Heller T,Lessells RJ,Wallrauch CG,et al.Community-based treatment for multidrug-resistant tuberculosis in rural Kwa-Zulu-Natal, South Africa. Int J Tuberc Lung Dis,2010,14(4):420-426.
[7] 唐神结,肖和平,张青.耐多药结核病化学治疗研究的新进展.中华结核和呼吸杂志,2009,32(8):617-620.
[8] Bang D, Lillebaek T, Thomsen V, et al.Multidrug-resistant tuberculosis: treatment outcome in Denmark, 1992—2007.Scand J Infect Dis,2010,42(4):288-293.
[9] 肖和平. 耐药结核病化学治疗指南(2010年).北京:人民卫生出版社,2011:1-60.
[10] WHO.Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. WHO/HTM/TB/2011.3. Geneva:World Health Organization, 2011.
[11] 唐神结,肖和平.广泛耐药结核病的现状与对策.中华医学杂志,2011,91(5):355-358.
[12] Anger HA, Dworkin F, Sharma S, et al. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000—2006. J Antimicrob Chemother,2010,65(4): 775-783.
[13] Tang SJ, Zhang Q, Zeng LH, et al. Efficacy and safety of line-zolid in the treatment of extensively drug-resistant tuberculosis.Jpn J Infect Dis,2011,64(6):509-512.
[14] Dheda K, Schwander SK, Zhu B, et al. The immunology of tuberculosis: from bench to bedside. Respirology,2010,15(3):433-450.
[15] Dlugovitzky D, Stanford C, Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB. Immunotherapy,2011,3(4):557-568.
[16] 唐神结,高文.临床结核病学.北京:人民卫生出版社,2011:214-244.
[17] 傅瑜.重视支气管结核的综合及介入治疗.中华结核和呼吸杂志,2011,34(5):325-326.
[18] 张杰,王娟,王婷,等.经支气管镜治疗良性瘢痕增生性气道狭窄方法的比较.中华结核和呼吸杂志,2011,34(5):334-338.
[19] Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality. Lancet,2010,375(9731): 2100-2109.
[20] 唐神结,肖和平.抗结核药物研究进展.中华全科医师杂志,2011,10(11):814-816.
[21] Diacon AH, Donald PR, Pym A,et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother,2012,56(6):3271-3276.
[22] 黄海荣,于霞,姜广路,等.利奈唑胺治疗耐多药结核病的初步评价.中国防痨杂志,2011,33(5):275-279.
[23] Wallis RS, Jakubiec W, Mitton-Fry M,et al.Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One,2012,7(1):e30479.
[24] Reddy VM, Dubuisson T, Einck L, et al.SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.J Antimicrob Chemother,2012,67(5):1163-1166.
[25] Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.. Antimicrob Agents Chemother, 2012, 55(12): 5485-5492.
[26] Vilaplana C, Montané E, Pinto S, et al. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.Vaccine,2010,28(4):1106-1116.
[27] Aagaard C, Hoang T, Dietrich J,et al.A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med, 2011,17(2): 189-194.
[28] Butov DA, Pashkov YN, Stepanenko AL, et al. Phase Ⅱb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines, 2011,9:3.
[29] Arjanova OV, Prihoda ND, Yurchenko LV, et al. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy, 2011,3(2):181-191.
[30] Armstead AL, Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine,2011,6:3281-3293.
[31] Jain SK, Gupta Y, Ramalingam L,et al.Lactose-conjugated PLGA nanoparticles for enhanced delivery of rifampicin to the lung for effective treatment of pulmonary tuberculosis. PDA J Pharm Sci Technol,2010,64(3):278-287.
[32] Shegokar R, Al Shaal L, Mitri K. Present status of nanoparticle research for treatment of tuberculosis. J Pharm Pharm Sci,2011,14(1):100-116.
[33] Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med,2011, 84(4):361-369.
[34] Kumar G, Malhotra S, Shafiq N,et al. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J Microencapsul,2011,28(8):717-728. |
京公安网备11010202008787号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
